Gastric cancer is an area of extreme unmet need where immuno-oncology (IO) treatments could provide a better survival outcome to patients. Merck & Co and two company partnerships, Bristol-Myers Squibb (BMS)/Ono and Merck KGaA/EMD Serono/Pfizer, are leading the development of immune checkpoint modulators in gastric cancer, according to GlobalData, a leading data and analytics company.
Among the 14 Phase II/III and III trials in gastric cancer assessing immune checkpoint modulators, eight are part of currently ongoing trials exploring the potential of immune checkpoint inhibitors in combination with either standard of care chemotherapy or other IO agents. GlobalData expects this strategy to be practice changing for gastric cancer patients over the next three years.
In September 2017, Merck & Co’s Keytruda and BMS/Ono’s Opdivo were both approved in heavily pretreated patients – the third line treatment of metastatic disease – by the FDA and Japan’s Ministry of Health, Labour and Welfare (MHLW), respectively. While all trial sponsors are trying to establish immune checkpoint modulators as new standard of care treatments in earlier settings, and therefore associating them with a larger number of gastric cancer patients, significant challenges remain to demonstrate survival benefit in the first or second lines of therapy.
Fern Barkalow, PhD, Oncology Director at GlobalData, comments: “In December 2017, two pivotal Phase III trials exploring immune checkpoint modulators in monotherapy failed to show any survival benefit, including Merck & Co’s Keytruda in the second line in the KEYNOTE-061 trial and Merck KGaA/Pfizer’s Bavencio in the third line of the metastaticsetting in the JAVELIN Gastric 300 trial.
The competitive landscape in gastric cancer is rapidly changing, and we forecast immune checkpoint modulators to show significant clinical and commercial impact by 2020.” - GlobalData